James Kyle Bryan, MD, is Chief Medical Officer of Novella Clinical where his guidance and expertise helps ensure the safety of patients during clinical trials. Having excelled at a career with nearly 25 years of experience as a hematologist and oncologist, Dr. Bryan currently holds an appointment as a clinical instructor for hematology and oncology at the University of Washington Medical Center and Harborview Medical Center. He also has over 20 years of drug development expertise with both pharmaceutical companies and global CROs and has co-authored over 20 peer-reviewed publications.
Andrew Zupnick, PhD, is Vice President, Oncology Strategy of Novella Clinical where he provides strategic guidance to the oncology and operational teams as well as consultative and account oversight for oncology customers. He has over 15 years of experience in oncology research and is in charge of pursuing new initiatives for the Oncology Division, including its recent sub-specialty focus in immuno-oncology. He holds a PhD in biological sciences, cell & molecular biology with a focus in oncology, from Columbia University.
As treatments target increasingly specific disease states, clinical trial design must evolve to generate enough data from relatively small sample populations